ALT — Q2 2026 Financial Report Analysis

Overview

Altimmune does not sell anything yet. It is a clinical-stage drug developer betting everything on one molecule, pemvidutide, an injectable that acts on two gut-hormone receptors at once (GLP-1, the target of Ozempic-type drugs, and glucagon, which pushes the liver to burn fat). It is being tested in three liver and alcohol-related conditions: MASH (fatty liver disease with inflammation and scarring), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For a company like this, the quarterly report is mostly about two questions: how much cash it is burning, and how long the cash in the bank lasts.

The second quarter of 2026 answered the second question decisively. Altimmune raised $211.1 million in an April share-and-warrant sale, on top of a $70.3 million direct sale to a single institutional investor in January, and ended June with $518.6 million of cash and investments, almost double the $273.5 million it held at the end of 2025. Spending rose modestly ahead of a large Phase 3 trial, and the quarterly net loss was $22.8 million, close to last year's $22.1 million. Loss per share fell to $0.12 from $0.27, but only because the number of shares more than doubled.

At a glance

• $518.6 million in cash and investments at June 30, 2026: at the first half's operating cash outflow of $45.2 million, that is several years of spending at today's pace, but the Phase 3 trial now enrolling will raise that pace.
• R&D spending of $18.7 million, up 8%: the mix shifted from finished mid-stage trials to the ALD trial and Phase 3 start-up costs, a sign the money is moving to the next stage rather than simply growing.
• 194.5 million shares outstanding, up from 110.9 million six months earlier, plus 75 million new warrants at $3.00: the funding came at the price of heavy dilution for existing shareholders.

Results for the quarter

All figures in US$ millions except per-share amounts. Source: Form 10-Q for the quarter ended June 30, 2026.

Takeaway: The 56% drop in loss per share is not an improvement in the business; it is entirely the result of a share count that more than doubled. What actually changed this quarter is the balance sheet: Altimmune swapped a funding problem for a dilution cost, and now has enough cash to start its Phase 3 MASH trial without needing to raise again on short notice.

Where the money went

Research and development (R&D) was $18.7 million, up $1.4 million, or 8%. The program-level breakdown shows the spending moving between trials rather than simply rising:

The company attributes the increase "primarily to the ongoing ALD trial as well as the startup costs for PERFORMA Phase 3 trial in MASH," partly offset by the completion of the RECLAIM trial in AUD and the IMPACT Phase 2b trial in MASH. MASH spending is lower than a year ago only because the big Phase 2b trial has ended and the Phase 3 trial had not yet enrolled a patient by June 30; that line should rise sharply from here.

General and administrative (G&A) costs, the overhead of running the company, rose 33% to $7.6 million, which the filing puts down to $0.6 million more in compensation and $1.1 million more in professional services. Overhead grew four times faster than R&D this quarter, which is worth watching in a company whose value rests almost entirely on its research.

Interest income quadrupled to $4.5 million as the larger cash pile was invested in money-market funds and marketable securities. That more than offset $1.1 million of interest on the company's loan from Hercules Capital, and is why the net loss grew only 3% even though the operating loss grew 14%.

Pipeline: what the cash is for

• MASH (PERFORMA Phase 3). The FDA granted pemvidutide Breakthrough Therapy Designation for MASH in January 2026, based on 24-week Phase 2b data showing statistically significant MASH resolution. Altimmune began enrolling patients in PERFORMA on August 3, 2026. The trial tests two doses over roughly 60 months, with an interim look after 52 weeks using liver biopsies to support an accelerated approval. That interim readout is expected in 2029.
• AUD (RECLAIM Phase 2). On July 28, 2026, after the quarter closed, Altimmune reported that the 24-week, roughly 100-patient trial met its primary goal: a statistically significant reduction in heavy drinking days per week versus placebo, with positive results on secondary measures the company describes as FDA registrational endpoints. It plans to request an End-of-Phase 2 meeting with the FDA, the step that agrees the design of a pivotal trial.
• ALD (RESTORE Phase 2). Enrollment of about 100 patients finished in July 2026. Patients are treated for 48 weeks, with liver stiffness at Week 48 as the main measure, so the primary result cannot arrive before the second half of 2027.

For context outside the filing: MASH already has approved treatments (Madrigal's Rezdiffra and, since 2025, Novo Nordisk's Wegovy), so pemvidutide will reach a market with established competitors. Altimmune's pitch, per its 48-week data, rests on improvements in non-invasive liver-scarring markers and weight loss that had not plateaued at the 1.8 mg dose, along with lower dropout rates than placebo. The alcohol-related indications have no GLP-1-class drug approved, which makes the AUD result potentially the more differentiated asset.

What the headline numbers hide

• Lower loss per share is a dilution artifact. Weighted shares rose from 81.5 million to 185.4 million. On last year's share count, this quarter's loss would have been about $0.28 per share, slightly worse than a year ago.
• More dilution is already priced in. The April deal sold 75 million common-stock warrants with a $3.00 exercise price, alongside the shares. If all are exercised, Altimmune receives another $225 million in gross proceeds, and shareholders absorb up to 75 million more shares.
• Cash burn tracks the accounting loss closely. Operating cash outflow for the first six months was $45.2 million against a net loss of $45.4 million. Non-cash charges ($6.2 million of stock compensation and $1.5 million of impairments) were offset by working-capital outflows (payables and accrued expenses paid down, receivables up $2.1 million), which the filing says added $5.9 million to the year-over-year increase in cash used.
• Small one-off charges. The company wrote down its Gaithersburg, Maryland office and lab lease by $0.7 million in Q1 and another $0.8 million in Q2 after announcing a headquarters move to Morristown, New Jersey. These are non-cash and modest.
• Expensive debt. Altimmune has drawn $35 million of a facility of up to $125 million from Hercules Capital, at a minimum rate of 9.70% (13.37% effective, including fees), maturing January 1, 2029, with interest-only payments currently running into late 2027. With over $500 million in cash, this is not a solvency issue, but it is costly money for a company whose $4.5 million of quarterly interest income implies it earns under 4% a year on its own cash.
• The burn rate is about to step up. The first half's spending reflected Phase 3 start-up work only. A global, multi-year Phase 3 outcomes trial is far more expensive than the Phase 2 work that has dominated recent R&D, so the $45 million half-year outflow is not a good guide to 2027–2029.

Outlook

Management gives no spending guidance. It says only that cash on hand as of June 30 is enough to fund operations "for at least a twelve-month period" from the filing date, based on expected 2026 and 2027 costs. That is the minimum statement accounting rules require, not a runway estimate.

Our read: the $518.6 million balance would cover more than five years at the first half's burn rate. Even if spending doubles or triples as PERFORMA enrolls, the company probably has enough to reach the 2029 interim MASH readout without returning to investors in a hurry, especially if the $3.00 warrants are exercised. The real uncertainty is scientific and competitive rather than financial: whether biopsy results in Phase 3 match the Phase 2b signal in a market that already has two approved drugs, and whether the positive AUD result turns into a pivotal program. Over the next few quarters, watch three things: how fast R&D rises once PERFORMA is enrolling at scale, the outcome of the AUD End-of-Phase 2 meeting with the FDA, and whether G&A keeps growing faster than research spending.